REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
The primary objective of the dose escalation (phase 1) part of the study is to assess the
safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum
tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in
patients with MET-altered Non-small cell lung cancer (NSCLC).
The primary objective of the dose expansion (phase 2) part of the study is to assess
preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR)
per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)